The global market for Hospital-Acquired Pneumonia Prevention was valued at US$ 178 million in the year 2024 and is projected to reach a revised size of US$ 276 million by 2031, growing at a CAGR of 6.5% during the forecast period.

Hospital-Acquired Pneumonia Prevention Market

Dental plaque is a biofilm formed by bacteria and their excreta, mainly distributed between the gums, and these bacteria cannot be removed using gauze or sponges. Bacteria in the mouth will quickly form a bacterial biofilm and cover the surface of the teeth within two hours after each cleaning. This biofilm protects common pathogens in the ICU, such as Staphylococcus aureus and Klebsiella pneumoniae. This biofilm must be destroyed before using antibacterial agents. If plaque and bacteria cannot be removed, they will move down to the balloon of the endotracheal tube. Since the balloon sealing cannot reach 100%, aspiration pneumonia will occur. Oral care is one of the effective means to prevent hospital-acquired pneumonia.

In hospitals, oral care is a vital measure to prevent aspiration pneumonia (i.e., hospital-acquired pneumonia), especially for bedridden patients, the elderly, patients with weakened immunity, and critically ill patients. This is because if the bacteria in the mouth are not effectively removed, they may enter the lungs through aspiration (i.e., swallowing saliva, food, or oral secretions), thus causing pneumonia. With the advancement of medical technology and the improvement of patients' awareness of hospital infection prevention and control, the prevention measures of hospital-acquired pneumonia have gradually gained attention. Globally, the prevention market of hospital-acquired pneumonia has gradually developed with the changes in public health needs and medical environment. The prevention market of hospital-acquired pneumonia included in this report is mainly oral care products.

Oral care products usually include oral care kits, moisturizing gels, mouthwashes, etc., among which oral care kits accounts for the largest proportion.

From the application point of view, patients in intensive care units (ICUs) are usually in an immunosuppressive state, and the risk of pneumonia infection is higher than that of patients in ordinary wards. Oral care has become an important part of reducing infection and preventing pneumonia. In order to reduce the incidence of hospital-acquired pneumonia in ICU patients, the use of oral care kits has become one of the standard preventive measures. The proportion in 2023 is approximately 60%.

The global key players of HAP prevention include Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical and Dentaid, etc. In 2023, in term of revenue of HAP prevention, the top 3 companies hold a share nearly 43%.

The problem of antibiotic resistance is becoming more and more serious, and traditional antibiotic treatment is no longer the only way to deal with hospital-acquired pneumonia. Preventive measures, such as the use of oral care kits, can effectively reduce bacterial loads and reduce the need for antibiotics, thereby alleviating the problem of drug resistance.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Hospital-Acquired Pneumonia Prevention, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hospital-Acquired Pneumonia Prevention.

The Hospital-Acquired Pneumonia Prevention market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Hospital-Acquired Pneumonia Prevention market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Hospital-Acquired Pneumonia Prevention manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Hospital-Acquired Pneumonia Prevention Market Report

Report Metric	Details
Report Name	Hospital-Acquired Pneumonia Prevention Market
Accounted market size in year	US$ 178 million
Forecasted market size in 2031	US$ 276 million
CAGR	6.5%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Oral Care Kit Moisturizer Gel Mouth Wash Others
Segment by Application	General Ward Intensive Care Unit
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical, Dentaid, Xttrium, Germiphene
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Hospital-Acquired Pneumonia Prevention manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Hospital-Acquired Pneumonia Prevention in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Hospital-Acquired Pneumonia Prevention Market growing?

Ans: The Hospital-Acquired Pneumonia Prevention Market witnessing a CAGR of 6.5% during the forecast period 2025-2031.

What is the Hospital-Acquired Pneumonia Prevention Market size in 2031?

Ans: The Hospital-Acquired Pneumonia Prevention Market size in 2031 will be US$ 276 million.

What is the market share of major companies in Hospital-Acquired Pneumonia Prevention Market?

Ans: In 2023, in term of revenue of HAP prevention, the top 3 companies hold a share nearly 43%.

Who are the main players in the Hospital-Acquired Pneumonia Prevention Market report?

Ans: The main players in the Hospital-Acquired Pneumonia Prevention Market are Stryker, Medline, Ecolab, Avanos, Dentsply Sirona, Intersurgical, Dentaid, Xttrium, Germiphene

What are the Application segmentation covered in the Hospital-Acquired Pneumonia Prevention Market report?

Ans: The Applications covered in the Hospital-Acquired Pneumonia Prevention Market report are General Ward, Intensive Care Unit

What are the Type segmentation covered in the Hospital-Acquired Pneumonia Prevention Market report?

Ans: The Types covered in the Hospital-Acquired Pneumonia Prevention Market report are Oral Care Kit, Moisturizer Gel, Mouth Wash, Others

1 Hospital-Acquired Pneumonia Prevention Market Overview

1.1 Product Definition

1.2 Hospital-Acquired Pneumonia Prevention by Type

1.2.1 Global Hospital-Acquired Pneumonia Prevention Market Value Comparison by Type (2024 VS 2031)

1.2.2 Oral Care Kit

1.2.3 Moisturizer Gel

1.2.4 Mouth Wash

1.2.5 Others

1.3 Hospital-Acquired Pneumonia Prevention by Application

1.3.1 Global Hospital-Acquired Pneumonia Prevention Market Value by Application (2024 VS 2031)

1.3.2 General Ward

1.3.3 Intensive Care Unit

1.4 Global Hospital-Acquired Pneumonia Prevention Market Size Estimates and Forecasts

1.4.1 Global Hospital-Acquired Pneumonia Prevention Revenue 2020-2031

1.4.2 Global Hospital-Acquired Pneumonia Prevention Sales 2020-2031

1.4.3 Global Hospital-Acquired Pneumonia Prevention Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Hospital-Acquired Pneumonia Prevention Market Competition by Manufacturers

2.1 Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Manufacturers (2020-2025)

2.2 Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Hospital-Acquired Pneumonia Prevention Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Hospital-Acquired Pneumonia Prevention, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Product Type & Application

2.7 Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Date of Enter into This Industry

2.8 Global Hospital-Acquired Pneumonia Prevention Market Competitive Situation and Trends

2.8.1 Global Hospital-Acquired Pneumonia Prevention Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Hospital-Acquired Pneumonia Prevention Players Market Share by Revenue

2.8.3 Global Hospital-Acquired Pneumonia Prevention Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Hospital-Acquired Pneumonia Prevention Market Scenario by Region

3.1 Global Hospital-Acquired Pneumonia Prevention Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Hospital-Acquired Pneumonia Prevention Sales by Region: 2020-2031

3.2.1 Global Hospital-Acquired Pneumonia Prevention Sales by Region: 2020-2025

3.2.2 Global Hospital-Acquired Pneumonia Prevention Sales by Region: 2026-2031

3.3 Global Hospital-Acquired Pneumonia Prevention Revenue by Region: 2020-2031

3.3.1 Global Hospital-Acquired Pneumonia Prevention Revenue by Region: 2020-2025

3.3.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Region: 2026-2031

3.4 North America Hospital-Acquired Pneumonia Prevention Market Facts & Figures by Country

3.4.1 North America Hospital-Acquired Pneumonia Prevention Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2031)

3.4.3 North America Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Hospital-Acquired Pneumonia Prevention Market Facts & Figures by Country

3.5.1 Europe Hospital-Acquired Pneumonia Prevention Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2031)

3.5.3 Europe Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Hospital-Acquired Pneumonia Prevention Market Facts & Figures by Region

3.6.1 Asia Pacific Hospital-Acquired Pneumonia Prevention Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Hospital-Acquired Pneumonia Prevention Sales by Region (2020-2031)

3.6.3 Asia Pacific Hospital-Acquired Pneumonia Prevention Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Hospital-Acquired Pneumonia Prevention Market Facts & Figures by Country

3.7.1 Latin America Hospital-Acquired Pneumonia Prevention Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2031)

3.7.3 Latin America Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Hospital-Acquired Pneumonia Prevention Market Facts & Figures by Country

3.8.1 Middle East and Africa Hospital-Acquired Pneumonia Prevention Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2031)

3.8.3 Middle East and Africa Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Hospital-Acquired Pneumonia Prevention Sales by Type (2020-2031)

4.1.1 Global Hospital-Acquired Pneumonia Prevention Sales by Type (2020-2025)

4.1.2 Global Hospital-Acquired Pneumonia Prevention Sales by Type (2026-2031)

4.1.3 Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Type (2020-2031)

4.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Type (2020-2031)

4.2.1 Global Hospital-Acquired Pneumonia Prevention Revenue by Type (2020-2025)

4.2.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Type (2026-2031)

4.2.3 Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Type (2020-2031)

4.3 Global Hospital-Acquired Pneumonia Prevention Price by Type (2020-2031)

5 Segment by Application

5.1 Global Hospital-Acquired Pneumonia Prevention Sales by Application (2020-2031)

5.1.1 Global Hospital-Acquired Pneumonia Prevention Sales by Application (2020-2025)

5.1.2 Global Hospital-Acquired Pneumonia Prevention Sales by Application (2026-2031)

5.1.3 Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Application (2020-2031)

5.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Application (2020-2031)

5.2.1 Global Hospital-Acquired Pneumonia Prevention Revenue by Application (2020-2025)

5.2.2 Global Hospital-Acquired Pneumonia Prevention Revenue by Application (2026-2031)

5.2.3 Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Application (2020-2031)

5.3 Global Hospital-Acquired Pneumonia Prevention Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Stryker

6.1.1 Stryker Company Information

6.1.2 Stryker Description and Business Overview

6.1.3 Stryker Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Stryker Hospital-Acquired Pneumonia Prevention Product Portfolio

6.1.5 Stryker Recent Developments/Updates

6.2 Medline

6.2.1 Medline Company Information

6.2.2 Medline Description and Business Overview

6.2.3 Medline Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Medline Hospital-Acquired Pneumonia Prevention Product Portfolio

6.2.5 Medline Recent Developments/Updates

6.3 Ecolab

6.3.1 Ecolab Company Information

6.3.2 Ecolab Description and Business Overview

6.3.3 Ecolab Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Ecolab Hospital-Acquired Pneumonia Prevention Product Portfolio

6.3.5 Ecolab Recent Developments/Updates

6.4 Avanos

6.4.1 Avanos Company Information

6.4.2 Avanos Description and Business Overview

6.4.3 Avanos Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Avanos Hospital-Acquired Pneumonia Prevention Product Portfolio

6.4.5 Avanos Recent Developments/Updates

6.5 Dentsply Sirona

6.5.1 Dentsply Sirona Company Information

6.5.2 Dentsply Sirona Description and Business Overview

6.5.3 Dentsply Sirona Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Dentsply Sirona Hospital-Acquired Pneumonia Prevention Product Portfolio

6.5.5 Dentsply Sirona Recent Developments/Updates

6.6 Intersurgical

6.6.1 Intersurgical Company Information

6.6.2 Intersurgical Description and Business Overview

6.6.3 Intersurgical Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Intersurgical Hospital-Acquired Pneumonia Prevention Product Portfolio

6.6.5 Intersurgical Recent Developments/Updates

6.7 Dentaid

6.7.1 Dentaid Company Information

6.7.2 Dentaid Description and Business Overview

6.7.3 Dentaid Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Dentaid Hospital-Acquired Pneumonia Prevention Product Portfolio

6.7.5 Dentaid Recent Developments/Updates

6.8 Xttrium

6.8.1 Xttrium Company Information

6.8.2 Xttrium Description and Business Overview

6.8.3 Xttrium Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Xttrium Hospital-Acquired Pneumonia Prevention Product Portfolio

6.8.5 Xttrium Recent Developments/Updates

6.9 Germiphene

6.9.1 Germiphene Company Information

6.9.2 Germiphene Description and Business Overview

6.9.3 Germiphene Hospital-Acquired Pneumonia Prevention Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Germiphene Hospital-Acquired Pneumonia Prevention Product Portfolio

6.9.5 Germiphene Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Hospital-Acquired Pneumonia Prevention Industry Chain Analysis

7.2 Hospital-Acquired Pneumonia Prevention Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Hospital-Acquired Pneumonia Prevention Production Mode & Process Analysis

7.4 Hospital-Acquired Pneumonia Prevention Sales and Marketing

7.4.1 Hospital-Acquired Pneumonia Prevention Sales Channels

7.4.2 Hospital-Acquired Pneumonia Prevention Distributors

7.5 Hospital-Acquired Pneumonia Prevention Customer Analysis

8 Hospital-Acquired Pneumonia Prevention Market Dynamics

8.1 Hospital-Acquired Pneumonia Prevention Industry Trends

8.2 Hospital-Acquired Pneumonia Prevention Market Drivers

8.3 Hospital-Acquired Pneumonia Prevention Market Challenges

8.4 Hospital-Acquired Pneumonia Prevention Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Hospital-Acquired Pneumonia Prevention Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Hospital-Acquired Pneumonia Prevention Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Hospital-Acquired Pneumonia Prevention Market Competitive Situation by Manufacturers in 2024

Table 4. Global Hospital-Acquired Pneumonia Prevention Sales (M Units) of Key Manufacturers (2020-2025)

Table 5. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Hospital-Acquired Pneumonia Prevention Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Hospital-Acquired Pneumonia Prevention Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Hospital-Acquired Pneumonia Prevention Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Hospital-Acquired Pneumonia Prevention, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Product Type & Application

Table 12. Global Key Manufacturers of Hospital-Acquired Pneumonia Prevention, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Hospital-Acquired Pneumonia Prevention by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hospital-Acquired Pneumonia Prevention as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Hospital-Acquired Pneumonia Prevention Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Hospital-Acquired Pneumonia Prevention Sales by Region (2020-2025) & (M Units)

Table 18. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Region (2020-2025)

Table 19. Global Hospital-Acquired Pneumonia Prevention Sales by Region (2026-2031) & (M Units)

Table 20. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Region (2026-2031)

Table 21. Global Hospital-Acquired Pneumonia Prevention Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Region (2020-2025)

Table 23. Global Hospital-Acquired Pneumonia Prevention Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Region (2026-2031)

Table 25. North America Hospital-Acquired Pneumonia Prevention Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2025) & (M Units)

Table 27. North America Hospital-Acquired Pneumonia Prevention Sales by Country (2026-2031) & (M Units)

Table 28. North America Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Hospital-Acquired Pneumonia Prevention Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Hospital-Acquired Pneumonia Prevention Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2025) & (M Units)

Table 32. Europe Hospital-Acquired Pneumonia Prevention Sales by Country (2026-2031) & (M Units)

Table 33. Europe Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Hospital-Acquired Pneumonia Prevention Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Hospital-Acquired Pneumonia Prevention Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Hospital-Acquired Pneumonia Prevention Sales by Region (2020-2025) & (M Units)

Table 37. Asia Pacific Hospital-Acquired Pneumonia Prevention Sales by Region (2026-2031) & (M Units)

Table 38. Asia Pacific Hospital-Acquired Pneumonia Prevention Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Hospital-Acquired Pneumonia Prevention Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Hospital-Acquired Pneumonia Prevention Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2025) & (M Units)

Table 42. Latin America Hospital-Acquired Pneumonia Prevention Sales by Country (2026-2031) & (M Units)

Table 43. Latin America Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Hospital-Acquired Pneumonia Prevention Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Hospital-Acquired Pneumonia Prevention Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Hospital-Acquired Pneumonia Prevention Sales by Country (2020-2025) & (M Units)

Table 47. Middle East and Africa Hospital-Acquired Pneumonia Prevention Sales by Country (2026-2031) & (M Units)

Table 48. Middle East and Africa Hospital-Acquired Pneumonia Prevention Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Hospital-Acquired Pneumonia Prevention Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Hospital-Acquired Pneumonia Prevention Sales (M Units) by Type (2020-2025)

Table 51. Global Hospital-Acquired Pneumonia Prevention Sales (M Units) by Type (2026-2031)

Table 52. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Type (2020-2025)

Table 53. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Type (2026-2031)

Table 54. Global Hospital-Acquired Pneumonia Prevention Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Hospital-Acquired Pneumonia Prevention Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Type (2020-2025)

Table 57. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Type (2026-2031)

Table 58. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Type (2020-2025)

Table 59. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Type (2026-2031)

Table 60. Global Hospital-Acquired Pneumonia Prevention Sales (M Units) by Application (2020-2025)

Table 61. Global Hospital-Acquired Pneumonia Prevention Sales (M Units) by Application (2026-2031)

Table 62. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Application (2020-2025)

Table 63. Global Hospital-Acquired Pneumonia Prevention Sales Market Share by Application (2026-2031)

Table 64. Global Hospital-Acquired Pneumonia Prevention Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Hospital-Acquired Pneumonia Prevention Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Application (2020-2025)

Table 67. Global Hospital-Acquired Pneumonia Prevention Revenue Market Share by Application (2026-2031)

Table 68. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Application (2020-2025)

Table 69. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Application (2026-2031)

Table 70. Stryker Company Information

Table 71. Stryker Description and Business Overview

Table 72. Stryker Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Stryker Hospital-Acquired Pneumonia Prevention Product

Table 74. Stryker Recent Developments/Updates

Table 75. Medline Company Information

Table 76. Medline Description and Business Overview

Table 77. Medline Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Medline Hospital-Acquired Pneumonia Prevention Product

Table 79. Medline Recent Developments/Updates

Table 80. Ecolab Company Information

Table 81. Ecolab Description and Business Overview

Table 82. Ecolab Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Ecolab Hospital-Acquired Pneumonia Prevention Product

Table 84. Ecolab Recent Developments/Updates

Table 85. Avanos Company Information

Table 86. Avanos Description and Business Overview

Table 87. Avanos Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Avanos Hospital-Acquired Pneumonia Prevention Product

Table 89. Avanos Recent Developments/Updates

Table 90. Dentsply Sirona Company Information

Table 91. Dentsply Sirona Description and Business Overview

Table 92. Dentsply Sirona Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Dentsply Sirona Hospital-Acquired Pneumonia Prevention Product

Table 94. Dentsply Sirona Recent Developments/Updates

Table 95. Intersurgical Company Information

Table 96. Intersurgical Description and Business Overview

Table 97. Intersurgical Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Intersurgical Hospital-Acquired Pneumonia Prevention Product

Table 99. Intersurgical Recent Developments/Updates

Table 100. Dentaid Company Information

Table 101. Dentaid Description and Business Overview

Table 102. Dentaid Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 103. Dentaid Hospital-Acquired Pneumonia Prevention Product

Table 104. Dentaid Recent Developments/Updates

Table 105. Xttrium Company Information

Table 106. Xttrium Description and Business Overview

Table 107. Xttrium Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 108. Xttrium Hospital-Acquired Pneumonia Prevention Product

Table 109. Xttrium Recent Developments/Updates

Table 110. Germiphene Company Information

Table 111. Germiphene Description and Business Overview

Table 112. Germiphene Hospital-Acquired Pneumonia Prevention Sales (M Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 113. Germiphene Hospital-Acquired Pneumonia Prevention Product

Table 114. Germiphene Recent Developments/Updates

Table 115. Key Raw Materials Lists

Table 116. Raw Materials Key Suppliers Lists

Table 117. Hospital-Acquired Pneumonia Prevention Distributors List

Table 118. Hospital-Acquired Pneumonia Prevention Customers List

Table 119. Hospital-Acquired Pneumonia Prevention Market Trends

Table 120. Hospital-Acquired Pneumonia Prevention Market Drivers

Table 121. Hospital-Acquired Pneumonia Prevention Market Challenges

Table 122. Hospital-Acquired Pneumonia Prevention Market Restraints

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources

Table 126. Authors List of This Report

List of Figures

Figure 1. Product Picture of Hospital-Acquired Pneumonia Prevention

Figure 2. Global Hospital-Acquired Pneumonia Prevention Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Hospital-Acquired Pneumonia Prevention Market Share by Type: 2024 & 2031

Figure 4. Oral Care Kit Product Picture

Figure 5. Moisturizer Gel Product Picture

Figure 6. Mouth Wash Product Picture

Figure 7. Others Product Picture

Figure 8. Global Hospital-Acquired Pneumonia Prevention Market Value by Application (2020-2031) & (US$ Million)

Figure 9. Global Hospital-Acquired Pneumonia Prevention Market Share by Application: 2024 & 2031

Figure 10. General Ward

Figure 11. Intensive Care Unit

Figure 12. Global Hospital-Acquired Pneumonia Prevention Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Hospital-Acquired Pneumonia Prevention Market Size (2020-2031) & (US$ Million)

Figure 14. Global Hospital-Acquired Pneumonia Prevention Sales (2020-2031) & (M Units)

Figure 15. Global Hospital-Acquired Pneumonia Prevention Average Price (US$/Unit) & (2020-2031)

Figure 16. Hospital-Acquired Pneumonia Prevention Report Years Considered

Figure 17. Hospital-Acquired Pneumonia Prevention Sales Share by Manufacturers in 2024

Figure 18. Global Hospital-Acquired Pneumonia Prevention Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Hospital-Acquired Pneumonia Prevention Players: Market Share by Revenue in Hospital-Acquired Pneumonia Prevention in 2024

Figure 20. Hospital-Acquired Pneumonia Prevention Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Hospital-Acquired Pneumonia Prevention Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Hospital-Acquired Pneumonia Prevention Sales Market Share by Country (2020-2031)

Figure 23. North America Hospital-Acquired Pneumonia Prevention Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Hospital-Acquired Pneumonia Prevention Sales Market Share by Country (2020-2031)

Figure 27. Europe Hospital-Acquired Pneumonia Prevention Revenue Market Share by Country (2020-2031)

Figure 28. Germany Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Hospital-Acquired Pneumonia Prevention Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Hospital-Acquired Pneumonia Prevention Revenue Market Share by Region (2020-2031)

Figure 35. China Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Taiwan Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Philippines Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Hospital-Acquired Pneumonia Prevention Sales Market Share by Country (2020-2031)

Figure 46. Latin America Hospital-Acquired Pneumonia Prevention Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Hospital-Acquired Pneumonia Prevention Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Hospital-Acquired Pneumonia Prevention Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. U.A.E Hospital-Acquired Pneumonia Prevention Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Hospital-Acquired Pneumonia Prevention by Type (2020-2031)

Figure 56. Global Revenue Market Share of Hospital-Acquired Pneumonia Prevention by Type (2020-2031)

Figure 57. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Type (2020-2031)

Figure 58. Global Sales Market Share of Hospital-Acquired Pneumonia Prevention by Application (2020-2031)

Figure 59. Global Revenue Market Share of Hospital-Acquired Pneumonia Prevention by Application (2020-2031)

Figure 60. Global Hospital-Acquired Pneumonia Prevention Price (US$/Unit) by Application (2020-2031)

Figure 61. Hospital-Acquired Pneumonia Prevention Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions